Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar.
Ingo KleiterAnthony L TraboulseeJacqueline PalaceTakashi YamamuraKazuo FujiharaAlbert SaizAdil JavedDavid MayesH-Christian von BüdingenGaelle KlingelschmittDaniela StokmaierJeffrey L BennettPublished in: Neurology(R) neuroimmunology & neuroinflammation (2022)
This study provides Class II evidence that satralizumab reduces the risk of relapse in patients with AQP4-IgG+ NMOSD beyond the first 96 weeks of treatment.
Keyphrases